BBIO Quote, Financials, Valuation and Earnings

Apellis Pharmaceuticals has a net margin of -143.55% compared to BridgeBio Pharma's net margin of -55.29%. BridgeBio Pharma's return on equity of -- beat Apellis Pharmaceuticals's return on equity of -96.34%.

BridgeBio Pharma has a consensus price target of $61.29, signalling upside risk potential of 31.77%. On the other hand Apellis Pharmaceuticals has an analysts' consensus of $35.60 which suggests that it could grow by 82.85%. Given that Apellis Pharmaceuticals has higher upside potential than BridgeBio Pharma, analysts believe Apellis Pharmaceuticals is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.154, which suggesting that the stock is 15.412% more volatile than S&P 500. In comparison Apellis Pharmaceuticals has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.72%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Apellis Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than Apellis Pharmaceuticals quarterly revenues of $166.8M. BridgeBio Pharma's net income of -$167.4M is lower than Apellis Pharmaceuticals's net income of -$92.2M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Apellis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 68.96x versus 3.13x for Apellis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ardelyx has a net margin of -143.55% compared to BridgeBio Pharma's net margin of -55.52%. BridgeBio Pharma's return on equity of -- beat Ardelyx's return on equity of -34.68%.

BridgeBio Pharma has a consensus price target of $61.29, signalling upside risk potential of 31.77%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 147.37%. Given that Ardelyx has higher upside potential than BridgeBio Pharma, analysts believe Ardelyx is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.154, which suggesting that the stock is 15.412% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are larger than Ardelyx quarterly revenues of $74.1M. BridgeBio Pharma's net income of -$167.4M is lower than Ardelyx's net income of -$41.1M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 68.96x versus 2.89x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -143.55% compared to BridgeBio Pharma's net margin of 21.63%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 8.72%.

BridgeBio Pharma has a consensus price target of $61.29, signalling upside risk potential of 31.77%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 19.45%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

BridgeBio Pharma has a beta of 1.154, which suggesting that the stock is 15.412% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.95% to investors and pays a quarterly dividend of $0.43 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than Pfizer quarterly revenues of $13.7B. BridgeBio Pharma's net income of -$167.4M is lower than Pfizer's net income of $3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 68.96x versus 2.23x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -143.55% compared to BridgeBio Pharma's net margin of 4.19%. BridgeBio Pharma's return on equity of -- beat TG Therapeutics's return on equity of 19.78%.

BridgeBio Pharma has a consensus price target of $61.29, signalling upside risk potential of 31.77%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 6.83%. Given that BridgeBio Pharma has higher upside potential than TG Therapeutics, analysts believe BridgeBio Pharma is more attractive than TG Therapeutics.

BridgeBio Pharma has a beta of 1.154, which suggesting that the stock is 15.412% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $116.6M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. BridgeBio Pharma's net income of -$167.4M is lower than TG Therapeutics's net income of $5.1M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 157.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 68.96x versus 15.78x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.